Regents of the University of Minnesota v. Glaxo Wellcome, Inc.

58 F. Supp. 2d 1036, 51 U.S.P.Q. 2d (BNA) 1567, 1999 U.S. Dist. LEXIS 8627, 1999 WL 553319
District Court, D. Minnesota·Decided June 8, 1999·No. Civil 98-2465 DSD/JMM·Published·Cited by 9 cases

Opinion

ORDER

DOTY, District Judge.

This matter is before the court on the objections of plaintiff to the order of United States Magistrate Judge John M. Mason dated March 16, 1999. Based on a review of the file, record, and proceedings, and for the reasons stated, the court affirms the magistrate judge’s order.

BACKGROUND

The facts underlying this dispute are not contested and are reviewed in the March 16, 1999, order at Magistrate Judge Mason. Procedurally, after plaintiff filed suit in Hennepin County District Court on October 16, 1998, defendant removed this action to federal court, invoking this court’s jurisdiction under 28 U.S.C. §§ 1331 and 1338(a). Plaintiff then filed a timely motion to remand to state court pursuant to 28 U.S.C. § 1447(c). The magistrate judge held that this matter was properly removed to federal court and jurisdiction exists to hear this case. Plaintiff has filed timely objections, which will be discussed below.

DISCUSSION

A motion to remand is considered a nondispositive matter that a magistrate judge can determine pursuant to 28 U.S.C. § 636(b)(1)(A). In examining plaintiffs objections, therefore, the court must affirm the order of the magistrate judge unless it is clearly erroneous or contrary to law. See 28 U.S.C. § 636(b)(1)(A); D.Minn.L.R. 72.1(b)(2); Banbury v. Omnitrition International, Inc., 818 F.Supp. 276, 279 (D.Minn.1993). Plaintiff has filed objections to both of the magistrate judge’s findings. Specifically, plaintiff argues that the magistrate judge erred in: (1) holding that the federal court has subject matter jurisdiction over this matter; and (2) the Eleventh Amendment does not bar removal.

Plaintiff first argues that this declaratory judgment action does not arise under the patent laws and no basis for federal jurisdiction exists. In response, defendant maintains that the court has original jurisdiction under 28 U.S.C. §§ 1331 and 1338(a). The parties do not dispute that the issue is whether, pursuant to the “well-pleaded complaint rule,” plaintiffs claim constitutes a suit “arising under” the patent laws of the United States.

As pointed out by the magistrate judge, the complaint seeks a declaratory judgment establishing that defendant must manufacture Ziagen in the United States. Report and Recommendation (Docket No. 30) at 6. The complaint also seeks a declaration that the manufacture, use, or sale of Ziagen the United States will infringe one or more of the Vince patents which are the subject of the License Agreement between the parties. Id. at 7. In the complaint, plaintiff avers that:

Ziagen, if manufactured, used, or sold in the United States would infringe upon *1038 certain of the U.S. Vince patents, including U.S. Patent No. 4,916,224, U.S. Patent No. 4,931,559, U.S. Patent No. 5,567,703, and U.S. Patent No. 5,631,370.

Complaint at ¶ 20. Plaintiff avers that defendant will not perform certain “material obligations and duties” established in the parties’ license agreement with respect to the manufacture and sale of Ziagen because of defendant’s contention that “the use or sale of Ziagen in the United States will not infringe any Vince Patents in the United States[.]” Complaint ¶ 24. Plaintiff maintains, however, that Article 5.1 of the license agreement “does require [defendant] to pay [plaintiff] a 10% royalty on sales of Ziagen in the United States because the use or sale of Ziagen in the United States will infringe one or more Vince Patents[.]” Complaint ¶ 25.

In its prayer for relief, therefore, plaintiff seeks “a declaration that the sale of Ziagen in the United States, accrues the obligation under Article 5.1 to pay royalties of 10% to the University as provided in the License Agreement, based upon one or more claims of one or more of the U.S. Vince Patents.” Complaint, Prayer for Relief at ¶ 1(a). In addition, plaintiff seeks a declaration that “sale of Ziagen manufactured in the United Kingdom accrues the obligation to pay the University royalties of 5% as provided in the License Agreement if the manufacture of Ziagen would infringe a valid claim of the Vince Patents in the United States, regardless of the actual place of manufacture.” Complaint, Prayer for Relief at ¶ 1(d).

The Supreme Court has held that:

A district court’s federal question jurisdiction ... extends over “only those cases in which a well-pleaded complaint establishes either that federal law creates the cause of action or that the plaintiffs right to relief necessarily depends an resolution of a substantial question of federal law,” Franchise Tax Board of California v. Construction Laborers Vacation Trust, 463 U.S. 1, 27-28, 103 S.Ct. 2841, 77 L.Ed.2d 420 (1983), in that “federal law is a necessary element of one of the well-pleaded claims,” id., at 13, 103 S.Ct. 2841. Linguistic consistency, to which we have historically adhered, demands that § 1338(a) jurisdiction likewise extend only to those cases in which a well-pleaded complaint establishes either that federal patent law creates the cause of action or that the plaintiffs right to relief necessarily depends on resolution of a substantial question of federal patent law, in that patent law is a necessary element of one of the well-pleaded claims.

Christianson v. Colt Industries Operating Corp., 486 U.S. 800, 808-09, 108 S.Ct. 2166, 100 L.Ed.2d 811 (1988). See also Scherbatskoy v. Halliburton Co., 125 F.3d 288, 291 (5th Cir.1997).

Free access — add to your briefcase to read the full text and ask questions with AI

Regents of the University of Minnesota v. Glaxo Wellcome, Inc., 58 F. Supp. 2d 1036, 51 U.S.P.Q. 2d (BNA) 1567, 1999 U.S. Dist. LEXIS 8627, 1999 WL 553319 (mnd 1999).

58 F. Supp. 2d 1036 (Regents of the University of Minnesota v. Glaxo Wellcome, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

California v. Atlantic Richfield Co.
488 F.3d 112 (Second Circuit, 2007)
People of the State of California, Ex Rel Bill Lockyer, Attorney General, Attorney General of the State of California v. Dynegy, Inc. Dynegy Power Marketing, Inc. Nrg Energy, Inc. Xcel Energy, Inc. West Coast Power LLC Cabrillo Power I LLC Cabrillo Power II LLC El Segundo Power LLC Long Beach Generation Llc, People of the State of California, Ex Rel Bill Lockyer, Attorney General of the State of California Bill Lockyer, Attorney General, Attorney General of the State of California v. Reliant Energy, Inc. Reliant Energy Services, Inc. Reliant Energy Power Generation, Inc. Reliant Resources, Inc. Reliant Energy Coolwater, LLC Reliant Energy Ellwood, LLC Reliant Energy Etiwanda, LLC Reliant Energy Mandalay, LLC Reliant Energy Ormond Beach, Llc, People of the State of California, Ex Rel Bill Lockyer, Attorney General of the State of California Bill Lockyer, Attorney General, Attorney General of the State of California v. Mirant Corporation Mirant California, L.L.C. Mirant Potrero L.L.C. Mirant Americas Energy Marketing, L.P. Mirant California Investments, Inc. Mirant Americas Inc. Southern Energy Golden States Holdings, Inc., People of the State of California, Ex Rel. Bill Lockyer, Attorney General, Attorney General of the State of California v. Reliant Energy, Inc. Reliant Energy Services, Inc. Reliant Energy Power Generation, Inc. Reliant Resources, Inc. Reliant Energy Coolwater, LLC Reliant Energy Ellwood, LLC Reliant Energy Etiwanda, LLC Reliant Energy Mandalay, LLC Reliant Energy Ormond Beach, LLC Mirant Corporation Mirant California, L.L.C. Mirant Delta, L.L.C. Mirant Potrero LLC Mirant Americas Energy Marketing, L.P. Mirant California Investments, Inc. Mirant Americas, Inc. Southern Energy Golden States Holdings, Inc. Dynegy, Inc. Dynegy Power Marketing, Inc. Nrg Energy, Inc. Xcel Energy, Inc. West Coast Power, L.L.C. Cabrillo Power I, L.L.C. Cabrillo Power II LLC El Segundo Power, L.L.C. Long Beach Generation LLC
375 F.3d 831 (Ninth Circuit, 2004)
California ex rel Lockyer v. Dynegy, Inc.
375 F.3d 831 (Ninth Circuit, 2004)
In Re Rezulin Products Liability Litigation
133 F. Supp. 2d 272 (S.D. New York, 2001)
In Re Texas
110 F. Supp. 2d 514 (E.D. Texas, 2000)